Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 10 | 2016 | 301 | 0.840 |
Why?
|
| European Continental Ancestry Group | 6 | 2017 | 1132 | 0.770 |
Why?
|
| Colorectal Neoplasms | 3 | 2017 | 208 | 0.740 |
Why?
|
| Pancreatic Neoplasms | 7 | 2016 | 131 | 0.700 |
Why?
|
| African Americans | 6 | 2017 | 1375 | 0.630 |
Why?
|
| Colonoscopy | 1 | 2017 | 41 | 0.590 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 75 | 0.560 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 153 | 0.550 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 388 | 0.510 |
Why?
|
| Rural Health | 1 | 2014 | 43 | 0.490 |
Why?
|
| Common Bile Duct Neoplasms | 4 | 2016 | 7 | 0.470 |
Why?
|
| Ampulla of Vater | 4 | 2016 | 7 | 0.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 94 | 0.460 |
Why?
|
| Oxidative Stress | 1 | 2014 | 223 | 0.430 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 20 | 0.400 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 438 | 0.390 |
Why?
|
| Appendiceal Neoplasms | 3 | 2017 | 81 | 0.390 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 19 | 0.350 |
Why?
|
| Middle Aged | 23 | 2018 | 10920 | 0.340 |
Why?
|
| Aged | 20 | 2018 | 9572 | 0.340 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 36 | 0.300 |
Why?
|
| Mutation | 3 | 2017 | 469 | 0.280 |
Why?
|
| Humans | 28 | 2018 | 29449 | 0.270 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 22 | 0.270 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.270 |
Why?
|
| Male | 22 | 2018 | 17969 | 0.270 |
Why?
|
| Adult | 17 | 2018 | 8511 | 0.270 |
Why?
|
| Dermatology | 2 | 2018 | 154 | 0.260 |
Why?
|
| Female | 21 | 2018 | 18341 | 0.260 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 20 | 0.250 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 28 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 189 | 0.250 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 711 | 0.240 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 3758 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2018 | 3135 | 0.230 |
Why?
|
| Gallbladder Neoplasms | 2 | 2012 | 33 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 638 | 0.200 |
Why?
|
| Survival Rate | 8 | 2017 | 796 | 0.200 |
Why?
|
| SEER Program | 3 | 2017 | 33 | 0.200 |
Why?
|
| Cytodiagnosis | 2 | 2018 | 16 | 0.190 |
Why?
|
| Bile Ducts | 2 | 2018 | 18 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2121 | 0.190 |
Why?
|
| Prognosis | 7 | 2017 | 1369 | 0.170 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 58 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 199 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2017 | 31 | 0.150 |
Why?
|
| Esophagectomy | 1 | 2017 | 15 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2017 | 16 | 0.150 |
Why?
|
| Pathology | 1 | 2017 | 20 | 0.150 |
Why?
|
| Incidence | 2 | 2017 | 1126 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 33 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 533 | 0.150 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 6 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2017 | 140 | 0.140 |
Why?
|
| Comorbidity | 2 | 2016 | 548 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 443 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 143 | 0.130 |
Why?
|
| Medicare | 1 | 2017 | 189 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 280 | 0.130 |
Why?
|
| Analgesics | 1 | 2016 | 126 | 0.130 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 6 | 0.130 |
Why?
|
| Electrons | 1 | 2015 | 11 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2014 | 2 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 179 | 0.130 |
Why?
|
| Georgia | 1 | 2014 | 13 | 0.120 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 29 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2015 | 88 | 0.120 |
Why?
|
| Isoprostanes | 1 | 2014 | 2 | 0.120 |
Why?
|
| beta Carotene | 1 | 2014 | 5 | 0.120 |
Why?
|
| Africa, Western | 1 | 2014 | 4 | 0.120 |
Why?
|
| Marital Status | 1 | 2014 | 20 | 0.120 |
Why?
|
| Carotenoids | 1 | 2014 | 9 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2014 | 34 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2015 | 92 | 0.120 |
Why?
|
| Medical Records | 1 | 2014 | 68 | 0.120 |
Why?
|
| Social Class | 1 | 2014 | 78 | 0.120 |
Why?
|
| Age Distribution | 1 | 2014 | 199 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 105 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 2423 | 0.110 |
Why?
|
| Gallbladder | 1 | 2012 | 2 | 0.110 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 3 | 0.110 |
Why?
|
| Polyps | 1 | 2012 | 8 | 0.110 |
Why?
|
| United States | 3 | 2017 | 3685 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 206 | 0.110 |
Why?
|
| Risk Factors | 2 | 2017 | 3596 | 0.110 |
Why?
|
| Adenoma | 1 | 2012 | 35 | 0.110 |
Why?
|
| Diet | 1 | 2014 | 356 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2017 | 1701 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 520 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 13 | 0.100 |
Why?
|
| Neoplasms | 1 | 2017 | 621 | 0.090 |
Why?
|
| Age Factors | 4 | 2016 | 1120 | 0.090 |
Why?
|
| Mucins | 3 | 2016 | 19 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1380 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 156 | 0.090 |
Why?
|
| Disease Progression | 3 | 2017 | 574 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2009 | 171 | 0.080 |
Why?
|
| Observer Variation | 2 | 2018 | 96 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 139 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2017 | 3123 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 282 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2017 | 440 | 0.060 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 13 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 729 | 0.060 |
Why?
|
| Adolescent | 3 | 2017 | 3278 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 727 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 337 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 796 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 5 | 0.040 |
Why?
|
| Appendectomy | 1 | 2017 | 15 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 2041 | 0.040 |
Why?
|
| Colectomy | 1 | 2017 | 25 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 31 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 71 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 77 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 293 | 0.040 |
Why?
|
| Diabetic Neuropathies | 1 | 2016 | 23 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1080 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 90 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 141 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 448 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 321 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 273 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2015 | 3 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 108 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 67 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 48 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 242 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 354 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 525 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 333 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 633 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 440 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 633 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mucin-2 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mucin-6 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 242 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 20 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2012 | 67 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 32 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 547 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1327 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 21 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 24 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 438 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 32 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2228 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 673 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 6 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 173 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2004 | 79 | 0.010 |
Why?
|